The Five Most Pivotal Psychedelics Studies So

New Post Public Reply Private Reply Replies (0) Message Board
NetworkNewsWire
225
The Five Most Pivotal Psychedelics Studies So Far

Numerous studies on psychedelics have been conducted since the substances went mainstream a couple of years ago. Since then, a lot has been unearthed about the therapeutic benefits these drugs possess. Here are some important studies on psychedelics that are currently being conducted or are complete.

Compass Pathways phase IIb trial

Compass Pathways published data on its psychedelic clinical trial, which used psilocybin therapy to manage treatment-resistant depression in 2021. Trial results show that at least 36% of the participants saw a considerable reduction in their symptoms three weeks after the treatment has ended, with almost 30% of these participants improving enough to enter remission.

MAPS phase III trial

The Multidisciplinary Association of Psychedelic Studies (MAPS) also published data on its phase III trial in 2021. The trial evaluated the effectiveness of MDMA therapy in treating severe post-traumatic stress disorder. The study included 90 participants, some of whom were survivors of sexual assault and war veterans who had, on average, suffered from post-traumatic stress disorder for roughly 14 years.

The study’s findings show that almost 90% of the participants had seen a decrease in their symptoms.

Imperial College of London phase II trial

Researchers at the Imperial College of London, led by Dr. Robin Carhart Harris, looked into the effectiveness of psilocybin therapy in the treatment of major depressive disorder. The researchers compared the therapy’s effectiveness with that of selective serotonin reuptake inhibitors, which are the most common treatment option for this mental health condition.

The study discovered that psilocybin was just as effective in treating depression as escitalopram, which is the SSRI that researchers used for their study. In their report, the researchers note that participants who received psilocybin saw their symptoms of depression fall eight points on the 27-point scale while the symptoms of those who were treated using SSRIs reduced by only six points.

Awakn Life Sciences phase II trial

At the start of this year, Awakn released results of its phase II trial that looked into the treatment of alcohol use disorder using ketamine. While ketamine has been used as an anesthetic since the 1970s, recent studies have shown that the psychedelic can be used to treat everything from addiction to depression. The study found that more than 85% of those who received ketamine treatments remained abstinent from alcohol.

Small Pharma phase I safety trial

Last year, Small Pharma published data on its DMT clinical trial. The objective of the trial was to test the drug’s effectiveness in treating major depressive disorder. The company has progressed its DMT formulation to phase IIa clinical trials.

All those studies have helped to bring psychedelics back into the mainstream, and companies such as Delic Holdings Corp. (CSE: DELC) (OTC: DELCF) can look forward to expanding their presence across the region as more psychedelic substances get approved for different medical indications.

NOTE TO INVESTORS: The latest news and updates relating to Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) are available in the company’s newsroom at https://ibn.fm/DELCF

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer


Delic Holdings Corp (DELCF) Stock Research Links

DELCF Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Duetti, CesiumAstro, and a Busy NYSE Capital Morning

Updated Category News Views 78

Three very different piles of money are jamming up the November 20 NYSE slate, and that contrast is the whole point. Private music catalogs, space-and-defense communications, and a new stock-and-bond ETF do not belong in the same bucket. Yet all three are competing for investor attention before the opening bell, alongside Danaos Corporation's 20th listing anniversary....

Continue Reading
Simmons Clarifies Texas Loan Exposure, But Risks Remain

Updated Category News Views 50

A $45 million discrepancy is not a rounding error, and Simmons First National has every reason to swat it down hard. The bank says recent reporting overstated financing tied to a Texas multifamily development at $133 million. Its stated total is roughly $88 million, with about $44 million participated to another financial institution. For shareholders in NASDAQ:SFNC, that...

Continue Reading
Story Cannabis Bets on Neighborly Thanksgiving Outreach

Updated Category News Views 58

A frozen turkey is not a grand strategy deck, thank goodness; it is dinner for a household that might be feeling the squeeze. Story Cannabis plans to hand out 840 of them on Tuesday, Nov. 24, splitting the giveaway between Columbus and Cleveland with former Ohio State and Dallas Cowboys running back Michael Wiley joining employees and volunteers. In a cannabis business...

Continue Reading
North Richland Hills Bets on Its Visitor Momentum Now

Updated Category News Views 65

A crowded family attraction map is a nice problem for a Texas city to have, and North Richland Hills is trying to turn that pile of assets into a cleaner regional tourism machine. On Nov. 20, 2026, the city introduced “The Place You Never Outgrow,” its first destination-marketing campaign, built with Flat Five Marketing. This is not a stock story in the usual...

Continue Reading
Kinross Lawsuit Puts Round Mountain Claims Under Fire

Updated Category News Views 0

A mine can swallow a rosy forecast faster than any spreadsheet admits. That is the ugly center of the proposed securities class action involving Kinross Gold: not merely that production guidance came down, but the allegation that investors were sold too much confidence before the operational reality at Round Mountain Phase S surfaced. NYSE:KGC dropped from $27.62 on...

Continue Reading
Webster First Takes Aim at the Youth Money Literacy Gap

Updated Category News Views 39

Money mistakes get expensive long before anyone calls them mistakes. That is the uncomfortable point beneath Webster First Federal Credit Union CEO John Thomasian's November 20, 2026 discussion of financial literacy: plenty of young adults are entering the real financial world with a card, a loan offer, and a phone full of banking apps, but no sturdy framework for using...

Continue Reading
TOP-REAL Tests Digital Monitoring in HER2 Cancer Care

Updated Category News Views 116

A cancer treatment can be extraordinarily potent and still get derailed by what happens on an ordinary Tuesday at home. That unglamorous gap between clinic visits is the whole point of TOP-REAL, a phase II academic study presented at ESMO AI & Digital Oncology 2026. Solti and its European partners are testing whether closer digital follow-up can catch trouble early enough...

Continue Reading
Flair's New Aviation Alliance Offers Options, Not Orders

Updated Category News Views 55

Aircraft shortages have a funny way of turning vague partnerships into very useful insurance policies. Flair Airlines, Phoenix Aviation Capital and Avia Solutions Group announced a Strategic Commercial Cooperation Agreement on Nov. 19, 2026, and the sensible reading is straightforward: the Canadian value carrier wants more ways to solve capacity and operational problems...

Continue Reading
Charter Investigation Puts ACP Exit Claims Under Lens

Updated Category News Views 13

Charter’s ACP hangover has grown from an operating headache into a governance question. Kahn Swick & Foti said on November 20, 2026, that it has begun investigating whether Charter Communications officers or directors breached fiduciary duties or otherwise broke state or federal law. That is not a finding of wrongdoing, and investors ought to keep that distinction...

Continue Reading
Arizona's Dry Climate Puts Scalp Health Under Stress

Updated Category News Views 65

Desert weather is unforgiving, and apparently the scalp does not get a pass. In a Nov. 20, 2026 discussion, Scottsdale and Tucson hair-restoration physician Dr. Sharon A. Keene frames Arizona hair concerns around something easy to overlook: the condition of the skin beneath the hair. That is a more sensible starting point than treating every strand in the shower like it...

Continue Reading

Top 5 Most Recently Viewed Articles

BlackBerry QNX and Pi Square Join Forces to Advance Indian Tech

Updated Category News Views 333

BlackBerry QNX Partners with Pi Square Technologies BlackBerry Limited (NYSE: BB) is experiencing a notable increase in share prices, reflecting growing investor confidence. Expanding Horizons for Engineers Recently, BlackBerry’s QNX division announced an exciting multi-year collaboration with Pi Square Technologies. This initiative aims to train thousands of engineers...

Continue Reading
Investors Urged to Act: Investigating DexCom Securities Claims

Updated Category News Views 67

Understanding the Ongoing Investigations into DexCom Faruqi & Faruqi, LLP, a prominent national securities law firm, is currently investigating potential claims on behalf of investors affected by losses in DexCom, Inc. (NASDAQ: DXCM). This inquiry is a direct response to significant concerns raised about the company's business practices and market performance. The Scope...

Continue Reading
Legal Battle Heats Up for Michigan Auto Attorney Over CURE

Updated Category News Views 299

Michigan Attorney Faces Legal Challenges Amid CURE Controversy In a recent turn of events, an attorney from Michigan is experiencing the challenges of navigating legal waters after speaking out against CURE Auto Insurance. The attorney, Steven M. Gursten, along with his firm Michigan Auto Law, is embroiled in lawsuits that highlight serious concerns about consumer...

Continue Reading
Investors of Joint Stock Company Kaspi.kz (KSPI) Take Action Now

Updated Category News Views 120

Investors of Joint Stock Company Kaspi.kz (NASDAQ: KSPI) Take Action Attention investors of Joint Stock Company Kaspi.kz, also known as KSPI! A recent report has raised serious concerns regarding the company's activities, prompting investors who have experienced losses to consider their options in filing a securities fraud lawsuit. These troubling developments are crucial...

Continue Reading
Investors Guide: Urgent Action Needed for Western Asset Fund

Updated Category News Views 130

Introduction to the Class Action The Rosen Law Firm, a prominent name in investor rights advocacy, is urging investors in the Western Asset Management Company mutual funds to take action before an important deadline. If you invested in the 'Western Asset US Core Bond Fund' or the 'Western Asset Core Plus Bond Fund' during the designated class period, this message is...

Continue Reading